

VACNO: The Universal Cancer Drug

**Carleton Hsia, Ph.D.
Chairman and CEO**


**AntiRadical Therapeutics LLC
2329 N. Career Avenue, B113
Sioux Falls, SD 57107**

**cjhsia@yahoo.com
949-272-6222**



VACNO: The Universal Cancer Drug

Metastases are responsible for
90% of cancer deaths



4 out of 10 Americans
will develop cancer






Cost of Cancer

- 1) New Cancer drugs would cost ~ \$ 30,000 in addition to Insurance**
- 2) 1.6 million x \$30,000 ~ \$50 billion for 2017**
- 3) Cancer Drug market ~ \$100 billion**
- 4) The human cost**



VACNO: The Universal Cancer Drug




**VACNO represents the discovery
of
a safe, affordable and universal
anti-metastasis drug
for
the reduction of death and
suffering
in
cancer patients worldwide**

UCSF

SANFORD[®]
RESEARCH




VACNO: The Universal Cancer Drug




**VACNO treatment reduces colony number and size
in a colony forming assay of triple negative breast cancer**

Albumin 12 μ M


VACNO 12 μ M



Inhibition of metastasis from flank tumor to lung



VACNO: The Universal Cancer Drug



I-SPY 2 Collaboration on TNBC Enables Rapid Approval of FDA Breakthrough Designation for VACNO

Year 1	Year 2	Year 3 & 4
<ul style="list-style-type: none"> ➤ GMP Production ➤ QC/Stability ➤ IND Submission 	<ul style="list-style-type: none"> ➤ I-SPY Phase 1b TNBC Clinical Trial ➤ FDA BTD 	<ul style="list-style-type: none"> ➤ I-SPY Phase 2 TNBC Clinical Trial ➤ Corporate Partnership for Clinical Trials of VACNO for treatment of other cancers
\$2 million	\$3 million	\$20 million



I-SPY 2 - Univ. of California, San Francisco

*Laura Esserman, M.D., M.B.A. Director, Carol Franc Buck
Breast Care Center*

I-SPY Phase 1b (SAFETY) conducted with 15 patients in the metastatic setting allows us to proceed to I-SPY 2 Clinical Trial of proliferative, genomically high-risk stage 2 and 3 disease, in the neoadjuvant setting with 60 patients at our 7 study sites.

Goal: To achieve FDA Breakthrough Therapy Designation for VACNO as a universal cancer treatment.

UCSF



VACNO: The Universal Cancer Drug

**Carleton Hsia, Ph.D.
Chairman and CEO**

**AntiRadical Therapeutics LLC
2329 N. Career Avenue, B113
Sioux Falls, SD 57107**

**cjhsia@yahoo.com
949-272-6222**

